Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France

HIV Medicine

Volumn 8, Issue 3, 2007, Pages 164-170

  Breton, G ^a   Lewden, C ^b   Spire, B ^b   Salmon, D ^c   Brun vezinet F ^a   Duong, M ^d   Allavena, C ^e   Leport, Catherine ^a   Salamon, R ^b,am   Raffi, F ^z,am   Chene G ^am   Moatti, J P ^am   Pierret, J ^am   Fleury, H ^am   Masquelier, B ^am   Peytavin, G ^am   Garraffo, R ^am   Costagliola, D ^am   Dellamonica, P ^aa,am   Morin, M ^am   Sobel, V ^am   Cuzin, L ^am   Dupon, M ^am   Duval, X ^am   Le Moing, V ^am   Marchou, B ^ak,am   May, T ^y,am   Morlat, P ^k,am   Rabaud, C ^am   Waldner Combernoux, A ^am   Collin, F ^am   Bursachi, P ^am   Delfraissy, J F ^am   Dormont, J ^am   Garre M ^m,am   Schmit, J L ^f   Chennebault, J M ^g   Faller, J P ^h   Dupond, J L ⁱ   Estavoyer, J M ⁱ   Humbert, P ⁱ   Krivitzky, A ^j   Dupon Longy Boursier, M ^k   Ragnaud, J M ^k   Granier, P ^l   Verdon, R ⁿ   Domart, Y ^o   Devidas, A ^p   Sobel, A ^q   Portier, H ^r   Perronne, C ^s   Lagarde, P ^t   Ceccaldi, J ^u   Peyramond, D ^v   Allard, C ^w   Reynes, J ^x   Cassuto, J P ^aa   Arsac, P ^ab   Bouvet, E ^ac   Bricaire, F ^ac   Bergmann, P ^ac   Cabane, J ^ac   Cessot, G ^ac   Girard, P M ^ac   Guillevin, L ^ac   Herson, S ^ac   Meyohas, M C ^ac   Molina, J M ^ac   Pialoux, G ^ac   Becq Giraudon, B ^ad   Jaussaud, R ^ae   Michelet, C ^af   Lucht, F ^ag   Debord, T ^ah   Lang, J M ^ai   De Jaureguiberry, J P ^aj   Besnier, J M ^al   Alfaro, C ^am   Alkaied, F ^am   Barennes, C ^am   Boucherit, S ^am   Bouhnik, A D ^am   Brunet Francois C ^am   Carrieri, M P ^am   Courcoul, M ^am   Couturier, F ^am   Ecobichon, J L ^am   Francois M ^am   Iordache, L ^am   Journot, V ^am   Kurkdji, P ^am   Lassalle, R ^am   Legrand, J P ^am   Lootvoet, E ^am   Pereira, E ^am   Preau M ^am   Protopopescu, C ^am   Surzyn, J ^am   Taieb, A ^am   Tourteau, F ^am   Villes, V ^am   Zouari, H ^am   more..

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c INSERM U379 ^*  (France)

^d HÔPITAL DU BOCAGE   (France)

^e HÔTEL DIEU   (France)

^f Clinical Center   (France)

^g Clinical Center   (France)

^h Clinical Center   (France)

ⁱ Clinical Center   (France)

^j Clinical Center   (France)

^k Clinical Center   (France)

^l Clinical Center   (France)

^m Clinical Center   (France)

ⁿ Clinical Center   (France)

^o Clinical Center   (France)

^p Clinical Center   (France)

^q Clinical Center   (France)

^r Clinical Center   (France)

^s Clinical Center   (France)

^t Clinical Center   (France)

^u Clinical Center   (France)

^v Clinical Center   (France)

^w Clinical Center   (France)

^x Clinical Research Center   (France)

^y Clinical Center   (France)

^z Clinical Center   (France)

^aa Clinical Center   (France)

^ab Clinical Center   (France)

^ac Clinical Center   (France)

^ad Clinical Center   (France)

^ae Clinical Center   (France)

^af Clinical Center   (France)

^ag Clinical Center   (France)

^ah Clinical Center   (France)

^ai Clinical Center   (France)

^aj Clinical Center   (France)

^ak Clinical Center   (France)

^al Clinical Center   (France)

^am NONE

more..

Author keywords

Access to treatment; Africa; ART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; AFRICA; ARTICLE; BIRTHPLACE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ABUSE; DRUG RESPONSE; FEMALE; FOLLOW UP; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEGRO; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; SEXUAL TRANSMISSION; SURVIVAL; UNEMPLOYMENT; VIRUS LOAD;

ADULT; AFRICA SOUTH OF THE SAHARA; AFRICA, NORTHERN; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 34250320908     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00447.x     Document Type: Article

References (23)

1. UNAIDS. AIDS Epidemic Update. http://www.unaids.org 2006.
2. Laurent C, Diakhate N, Gueye NF et al. The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS 2002; 16: 1363-1370.
3. Laurent C, Ngom Gueye NF, Ndour CT et al. ANRS 1215/1290 Study Group. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1 infencted adults. J Acquir Immune Defic Syndr 2005; 38: 14-17.
4. Weidle PJ, Malamba S, Mwebaze R et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance. Lancet 2002; 360: 34-40.
5. Weidle PJ, Downing R, Sozi C et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative-Uganda. AIDS 2003; 3 Suppl: S39-S48.
6. Vergne L, Kane CT, Laurent C et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese initiative of access to antiretroviral therapy. AIDS 2003; 3 Suppl: S31-S38.
7. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. 2003; 17: 1369-1375.
8. Laniece I, Ciss M, Desclaux A et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003; 3 Suppl: S103-S108.
9. Hamers FF, Downs AM. The changing face of the HIV epidemic in western Europe: What are the implications for public health policies? Lancet 2004; 364: 83-94.
10. Institut de veille sanitaire. Premiers résultats du nouveau dispositif de surveillance de l'infection àVIH et situation du sida au 30 septembre 2003. Bull Epidemiol Hebdo 2004; 24-25: 102-110.
11. Le Moing V, Chene G, Carrieri MP et al. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr 2001; 27: 372-376.
12. Carrieri P, Cailleton V, Le Moing V et al. The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001; 28: 232-239.
13. Mocroft A, Kirk O, Barton SE et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999; 13: 943-950.
14. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly antiretroviral therapy. AIDS 2002; 16: 1139-1146.
15. Jensen-Fangel S, Pedersen L, Pedersen C et al. The effect of race/ ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35: 1541-1548.
16. Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and Immunologic Response to Highly Active Antiretroviral in Indigenous and Nonindigenous HIV-1-Infected Patients in The Netherlands. J Acquir Immune Defic Syndr 2004; 36: 943-950.
17. Staehelin C, Egloff N, Rickenbach M, Kopp C, Furrer H; Swiss HIV Cohort Study. Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: A single center study of epidemiologic migration-specific and clinical features. AIDS Patient Care STDS 2004; 18: 665-675.
18. Burns FM, Fakoya AO, Copas AJ, French PD. Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy. AIDS 2001; 15: 2453-2455.
19. Boyd AE, Murad S, O'Shea S, de Ruiter A, Watson C, Easterbrook PJ. Ethnic differences in stage of presentation of adults newly diagnosed with HIV-1 infection in south London. HIV Med 2005; 6: 59-65.
20. van den Berg JB, Hak E, Vervoort SC et al. Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy. HIV Med 2005; 6: 299-306.
21. Carrieri MP, Raffi F, Lewden C et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: A 3-year follow-up study. Antivir Ther 2003; 8: 585-594.
22. Anglaret X, Diagbouga S, Mortier E et al. CD4 + T-lymphocyte counts in HIV infection: Are European standards applicable to African patients? J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 361-367.
23. WHO. The World Health Report 2000. http//www.who.Int/2000.